US FDA hits another Indian drugmaker over data integrity issues

By Dan Stanton

- Last updated on GMT

US FDA hits another Indian drugmaker over data integrity issues

Related tags Food and drug administration

Sri Krishna Pharmaceuticals has been hit with a warning letter after the US FDA found problems with quality data at a site in Hyderabad, India.

The US Food and Drug Administration (FDA) issued the Warning on April 1 but published the letter​ yesterday, detailing significant violations of current good manufacturing practice (CGMP) at Sri Krishna’s Unit II finished formulation plant in Nacharam, Hyderabad.

The violations centred on problems with data observed during an inspection in December 2014, including laboratory records failing to contain all raw data generated during each test, and the firm’s quality unit using incomplete records to make batch release decisions in support of regulatory submissions to the Agency. For example:

“A QC analyst injected eleven identically or similarly named samples for impurity and assay analysis approximately one to fifteen seconds apart from one another… A second analyst injected eight similarly named impurity and assay samples approximately twelve to sixteen seconds apart,”​ the Agency wrote. “Neither analyst reported all results obtained during testing.”

“The laboratory incident reports concluded the first analyst deleted 28 original files due to pressure fluctuations and ghost peaks, while the second analyst deleted original trial injections of working standard and sample testing data due to a problem associated with peak shape.

“However, your laboratory incident reports provide no evidence to support these conclusions. Both analysts also changed the clock prior to reanalyzing the samples.”

Sri Krishna did not respond when contacted by in-Pharmatechnologist.com.

Integrity Issues

The Warning is the latest to be issued to an Indian drug or API maker based on data integrity problems. According to Regulatory Affairs Professionals Society (RAPS),​ 15 were slammed with Warning Letters between May 2013 and January 2015 due to problems with their data.

But the problem is not restricted to Indian drugmakers, as facilities in Italy and the Czech Republic (or ‘Czechia’​) have also been hit with warnings over data.

The FDA is looking to address the problem, and last week issued draft guidance​ consisting of 18 questions and answers aimed at assisting drugmakers to ensure the quality of their data, including how and when to limit access to computer systems controlling data input.

Related news

Show more

Related product

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Follow us

Webinars

Headlines